JP2019511240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511240A5 JP2019511240A5 JP2018554450A JP2018554450A JP2019511240A5 JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5 JP 2018554450 A JP2018554450 A JP 2018554450A JP 2018554450 A JP2018554450 A JP 2018554450A JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5
- Authority
- JP
- Japan
- Prior art keywords
- neural stem
- human neural
- disease
- stem cells
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322652P | 2016-04-14 | 2016-04-14 | |
| US62/322,652 | 2016-04-14 | ||
| PCT/US2017/027504 WO2017180926A1 (en) | 2016-04-14 | 2017-04-13 | Genome editing of human neural stem cells using nucleases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511240A JP2019511240A (ja) | 2019-04-25 |
| JP2019511240A5 true JP2019511240A5 (enExample) | 2020-05-14 |
| JP7197363B2 JP7197363B2 (ja) | 2022-12-27 |
Family
ID=60037918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554450A Active JP7197363B2 (ja) | 2016-04-14 | 2017-04-13 | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170298348A1 (enExample) |
| EP (1) | EP3443085B1 (enExample) |
| JP (1) | JP7197363B2 (enExample) |
| CN (1) | CN109312308A (enExample) |
| AU (2) | AU2017250683A1 (enExample) |
| CA (1) | CA3020181A1 (enExample) |
| SG (1) | SG11201808920RA (enExample) |
| WO (1) | WO2017180926A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP4434589A3 (en) | 2015-10-23 | 2025-05-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110075319A (zh) * | 2019-04-29 | 2019-08-02 | 白涛 | 一种抗遗传病生物导弹 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230355553A1 (en) * | 2020-02-11 | 2023-11-09 | University Of Virginia Patent Foundation | Compositions and methods for treating and/or preventing ocular disorders |
| EP4093859A4 (en) * | 2020-03-11 | 2023-06-14 | Remotor Therapeutics, Inc. | Methods and materials for disseminating a protein throughout the central nervous system |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| AU2021283272A1 (en) * | 2020-06-02 | 2023-01-19 | Catalent Pharma Solutions, Llc | Cell lines with multiple docks for gene insertion |
| CN111925998A (zh) * | 2020-06-09 | 2020-11-13 | 广州再生医学与健康广东省实验室 | 模拟SARS-CoV-2感染的系统及其制备方法与应用 |
| WO2022163770A1 (ja) * | 2021-01-28 | 2022-08-04 | 国立研究開発法人理化学研究所 | ゲノム編集ツールの評価方法 |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217565B2 (en) | 1999-02-12 | 2007-05-15 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7105150B2 (en) | 1999-02-12 | 2006-09-12 | Stemcells California, Inc. | In vivo screening methods using enriched neural stem cells |
| US7037719B1 (en) | 1999-02-12 | 2006-05-02 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7381561B2 (en) | 2002-08-27 | 2008-06-03 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| ES2828663T3 (es) * | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
| PL4289948T3 (pl) * | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| CN105142669B (zh) * | 2012-12-06 | 2018-07-03 | 西格马-奥尔德里奇有限责任公司 | 基于crispr的基因组修饰和调控 |
| CN105121648B (zh) * | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| CA2926078C (en) * | 2013-10-17 | 2021-11-16 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| CA2930590C (en) * | 2013-11-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineering neural stem cells using homologous recombination |
| EP3152319A4 (en) * | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
-
2017
- 2017-04-13 WO PCT/US2017/027504 patent/WO2017180926A1/en not_active Ceased
- 2017-04-13 US US15/487,309 patent/US20170298348A1/en not_active Abandoned
- 2017-04-13 SG SG11201808920RA patent/SG11201808920RA/en unknown
- 2017-04-13 AU AU2017250683A patent/AU2017250683A1/en not_active Abandoned
- 2017-04-13 EP EP17783170.8A patent/EP3443085B1/en active Active
- 2017-04-13 CA CA3020181A patent/CA3020181A1/en active Pending
- 2017-04-13 CN CN201780036763.3A patent/CN109312308A/zh active Pending
- 2017-04-13 JP JP2018554450A patent/JP7197363B2/ja active Active
-
2023
- 2023-01-03 US US18/092,911 patent/US20230250423A1/en active Pending
- 2023-07-24 AU AU2023208065A patent/AU2023208065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511240A5 (enExample) | ||
| US20250257343A1 (en) | Nucleic acid-based therapeutics | |
| JP7197363B2 (ja) | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 | |
| Ichim et al. | Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report | |
| JP2022000470A (ja) | 核酸製品及びその投与方法 | |
| Hedlund et al. | REVIEW ARTILCE: Cell therapy and stem cells in animal models of motor neuron disorders | |
| Garbossa et al. | New strategies for repairing the injured spinal cord: the role of stem cells | |
| US20260022400A1 (en) | Vectors for the treatment of friedreich's ataxia | |
| Hannallah et al. | Gene therapy in orthopaedic surgery | |
| Behl et al. | Gene therapy in the management of Parkinson’s disease: potential of GDNF as a promising therapeutic strategy | |
| US20030045830A1 (en) | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis | |
| RU2020125769A (ru) | Олигонуклеотиды для модуляции экспрессии tmem106b | |
| Phillips | Gene, stem cell, and future therapies for orphan diseases | |
| Bambakidis et al. | Endogenous stem cell proliferation after central nervous system injury: alternative therapeutic options | |
| Ebrahimi et al. | In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification | |
| Isaac Chen et al. | Neural stem cells as biological minipumps: a faster route to cell therapy for the CNS? | |
| Papadopoulos et al. | Gene therapies in clinical trials | |
| US20250115906A1 (en) | Schwann cell-specific promoter | |
| Bhagwat et al. | Neurogenesis: Gene-Based Strategies for Treating Ischemic Stroke | |
| Verhaagen et al. | Gene Therapy for Spinal Cord Injury | |
| O’Carroll et al. | Viral vector gene therapy approaches for regeneration and repair in spinal cord injury | |
| Simonato et al. | Gene Therapy for Neurological Diseases | |
| Li | Gene Therapy as a Frontier in Pharmacological Treatment | |
| Bertolotti | Zinc finger nuclease-boosted gene targeting and synergistic transient regenerative gene therapy for long-term stem cell gene therapy | |
| WO2020219870A1 (en) | Crispr/cas9 gene editing of atxn2 for the treatment of spinocerebellar ataxia type 2 |